platoseedplatoseed
mRNA therapeutics to extend healthspan entering clinical trials
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.
Rejuvenation Technologies focuses on reversing cellular aging by lengthening telomeres using telomerase activation via mRNA, with a pipeline targeting age-related diseases. The company emphasizes a targeted, temporary approach designed for safety and precision, and is advancing toward clinical trials.
The product uses modified mRNA to temporarily activate telomerase in specific cells, delivered via a proprietary lipid nanoparticle system to ensure tissue-specific targeting. The treatment is designed to transiently lengthen telomeres, enabling controlled cellular rejuvenation while monitoring telomere length and biomarkers to optimize outcomes. The approach emphasizes safety through temporary activation and targeted delivery, with clinical trial pathways planned to evaluate efficacy in pulmonary fibrosis, chronic liver disease, and hematologic indications.
Who it’s for: Biotech and pharmaceutical researchers and developers; clinical trial participants and care providers in pulmonary fibrosis, liver disease, and hematologic disorders; healthcare institutions involved in regenerative medicine.
Active research program with clinical trial planning and multiple trial indications; regulatory pathway planning mentioned
John Ramunas, PhD, invented TERT mRNA telomere extension at Stanford in Helen Blau's lab — reversing a decade of telomere shortening in one treatment. 50+ granted patents across 7 families through 2046. Preclinical efficacy in 4 organ systems. FDA INTERACT cleared. Khosla Ventures seed. YC S18. Raising $10M seed extension ($2M wired) for 3 clinical trials — Phase I readout Q3 2027. Subject #1 in first human trial.
New therapeutics to rejuvenate tissue and treat age-related diseases
Next-generation mRNA platform to solve cancer, COVID and climate.
